Cell therapy after surgery for stomach cancer with CLDN18.2
Part of Cancer, Digestive system clinical trials.
This trial tests a new type of cell therapy (CT041) given after surgery and chemotherapy to prevent stomach cancer from coming back. It is for people whose tumors have a specific protein (CLDN18.2) and who have already had standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of stomach or where the stomach meets the esophagus cancer called adenocarcinoma.
- Your tumor has a high amount of a protein called Claudin18.2 (at least 70% of cells show it).
- You had a specific type of stomach cancer surgery (D2 gastrectomy) and all visible cancer was removed (R0).
- You finished a standard course of chemotherapy after your surgery, or your doctor decided you could not complete it.
- You have not had any cancer cells come back or spread since your surgery.
- You are between 18 and 75 years old, and your overall health is good (ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy (CT041) for people with advanced stomach or gastroesophageal junction cancer that has a specific marker called CLDN18.2. It is given after initial chemotherapy to try to keep the cancer from growing.
This trial tests an experimental therapy for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy targets a specific protein (CLDN18.2) found on cancer cells. The goal is to see if this approach can help control the disease.
This trial tests a combination of experimental drugs (IBI343, Sintilimab, and chemotherapy) before and after surgery for a specific type of stomach cancer that is CLDN18.2 positive. The goal is to see if this treatment shrinks the tumor and helps prevent the cancer from coming back.
This study tests a combination of three treatments—JS107, toripalimab (an immunotherapy), and chemotherapy—for advanced stomach cancer that has a specific protein marker called CLDN18.2. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new therapy called CT0494BCP for advanced stomach cancer (including cancers at the junction between the esophagus and stomach) that hasn't responded to at least two prior treatments. The therapy is designed to target a specific protein called CLDN18.2 found on your cancer cells, combined with immune-boosting treatment.
This trial tests a three-drug combination (anlotinib, TQB2450, and nab-paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative and has progressed after prior treatment with a CLDN18.2-targeted regimen. The goal is to see if this new combination can shrink tumors and help patients live longer.
Hear when a new Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.